MANAGEMENT TACTICS OF PATIENTS WITH HYPERPLASTIC SYNDROME AND ANEMIA

Abstract

Abstract. The study of this clinical case made it possible to demonstrate the effectiveness of the management tactics of a patient with hyperplastic syndrome and anemia using hormone therapy with Buserelin- Long (an agonist of Hh-RG) for six months, followed by an operative stage (uterine artery embolization). The patient had relief of chronic pelvic pain by the third month of treatment with Buserelin -Long. In the future, the patient did not have a resumption of pain syndrome. During the control examination of the patient six months after the start of treatment, positive dynamics in the treatment of the hyperplastic process was revealed, expressed in a decrease in the size of intramural myomatous nodes, the absence of recurrence of the endometrial hyperplastic process, relief of pain and abnormal uterine bleeding. At the initial treatment of the patient, clinical and laboratory data were revealed confirming her chronic posthemorrhagic iron deficiency anemia. The indicators of clinical and biochemical blood tests reached the limits of reference values during the control examination after 6 months of Buserelin –Long therapy, which indicates the effectiveness of this management tactic in patients with hyperplastic syndrome and anemia. No adverse reactions were detected during treatment. The patient noted the good tolerability of the drug as well as the rapid and effective relief of the manifestations of the disease. Thus, based on the study of this clinical case, we can conclude about the effectiveness of the proposed management tactics for a patient with hyperplastic syndrome and anemia and recommend the use of this type of therapy in patients with similar pathology.